- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class: Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|No information available.|
|Summary of Clinical Use|
|Approved first in Japan, for the treatment of relapsed or refractory adult T cell leukemia/lymphoma. The 2018 EMA and FDA approvals allow Poteligeo® to be used as a treatment for two rare cutaneous T cell lymphomas; relapsed or refractory mycosis fungoides or Sézary syndrome (following at least one prior systemic therapy). In Europe the drug has EMA orphan designation for the treatment of cutaneous and peripheral T cell lymphomas.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Targets CCR4 on immunosuppressive Treg cells that have been recruited to the tumour microenvironment by CCR4 ligands such as CCL17 and CCL22 which are produced by intratumoural dendritic cells and macrophages. The resulting reduction in Treg suppression of Teff cell activity facilitates improved immune cell-mediated tumour cell killing.|
For extended ADME data see the following:
European Medicines Agency (EMA)